Akero Therapeutics Q2 net income just shy of estimates, cash position strong

Akero Therapeutics

08/08/2025 12:25

Overview

Akero Q2 net loss just shy of analyst expectations, per LSEG data

Operating income beats estimates, reflecting controlled expenses, per LSEG data

Outlook

Akero's cash reserves expected to fund operations into 2028

Result Drivers

R&D EXPENSES - R&D costs increase due to ongoing clinical studies and manufacture of clinical supplies

HIGHER COSTS - General costs increase lifting total operating expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
Miss
-$70.50 mln
-$70.10 mln (5 Analysts)
Q2 Operating Income
In line
-$80.87 mln
-$80.90 mln (5 Analysts)
Q2 Basic EPS
-$0.86
Q2 Operating Expenses
$80.87 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Akero Therapeutics Inc is $75.00, about 32.7% above its August 7 closing price of $50.45

Press Release: ID:nGNXddhVM

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)